Back to results
US 2020/0345795 A1Published application
Modulation of intestinal microbiota in pre-diabetes and type 2 diabetes
AssigneeMedlab IP Pty Ltd
InventorsLuis VITETTA, Talia PALACIOS
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeMedlab IP Pty Ltd
InventorsLuis VITETTA, Talia PALACIOS
Estimating the term…
Provided herein are methods for modulating the intestinal microbial profile and for reducing intestinal dysbiosis in type 2 diabetic or pre-diabetic subjects, comprising administering metformin or a derivative or salt thereof and one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii. Also provided are methods for treating type 2 diabetes or an associated metabolic complication or condition and for delaying the onset of type 2 diabetes in pre-diabetic subjects, comprising administering one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis sub sp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii.
A method for modulating the intestinal microbial profile in a type 2 diabetic or pre-diabetic subject, the method comprising administering to the subject metformin or a derivative or salt thereof and one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii, whereby the modulation of the intestinal microbial profile resulting from said administration comprises a decrease in abundance of pathogenic bacteria or bacteria that do not tolerate the host and/or an increase in the abundance of bacteria that tolerate the host.
A method for reducing intestinal dysbiosis in a type 2 diabetic or pre-diabetic subject, the method comprising administering to the subject metformin or a derivative or salt thereof and one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii.
A method for treating type 2 diabetes or a metabolic complication or condition associated therewith in a subject, the method comprising administering to the subject one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii.
A method for delaying or inhibiting the onset of type 2 diabetes in a pre-diabetic subject, the method comprising administering to the subject one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii.
A composition for treating type 2 diabetes or a metabolic complication or condition associated therewith, for delaying or inhibiting the onset of type 2 diabetes, or for modulating the intestinal microbiota in a type 2 diabetic or pre-diabetic subject, the composition comprising metformin or a derivative or salt thereof and one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii.
Dependencies are inferred from the claim text.